InvestSMART

Anteris Technologies Ltd (ASX:AVR)

ALERT: Price-sensitive ASX Announcement for AVR
Current share price for AVR : $14.120 5.21 (58.47%)+
Announcement
Release
23 Jan 2026 9:37AM
Price at Release
$8.910
Full Release
download
Summary
Anteris Technologies Ltd announced a strategic investment of $US 90 million from Medtronic, contributing to a total of $US 320 million in capital raises. This funding will support the PARADIGM trial and commercialization of the DurAVR® Transcatheter Heart Valve (THV). The PARADIGM trial is a significant randomized controlled trial aimed at evaluating the DurAVR® THV against current TAVR options. Medtronic's investment signifies a commitment to advancing innovation in TAVR, with the collaboration potentially expanding into additional strategic areas. The DurAVR® THV, featuring a biomimetic design and ADAPT® tissue technology, aims to provide improved patient outcomes in aortic stenosis treatment.
Key Points
  • Anteris Technologies received a strategic investment of $US 90 million from Medtronic.
  • This investment is part of a $US 320 million aggregate capital raise.
  • The funds will support the global pivotal PARADIGM trial and commercialization of the DurAVR® Transcatheter Heart Valve (THV).
  • The PARADIGM trial is a randomized controlled trial comparing DurAVR® THV with existing TAVRs.
  • Medtronic's investment aligns with advancing transcatheter aortic valve replacement (TAVR) innovation.
  • DurAVR® THV features biomimetic design using ADAPT® tissue technology.
  • The collaboration may expand into other strategic areas in the future.
  • Anteris is committed to improving the lives of patients with aortic stenosis.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.